Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 20, 2006

View Archived Issues

Low blood and tumor tissue levels of tasquinimod sufficient for antiangiogenic actions

M.D. Anderson and Baylor team up in asthma and allergic diseases

Preclinical and clinical antiplatelet efficacy of pasugrel demonstrated

Sativex and placebo show similar significant efficacy in patients with painful diabetic neuropathy

Safety and efficacy of SB-509 demonstrated in a phase I trial in patients with diabetic neuropathy

SGLT-2 inhibitor AVE-2268 effectively lowers blood glucose and urinary glucose excretion in rodents

KW-3902 improves diuresis and renal function in patients with heart failure and renal impairment

Analgesic properties of the anticancer agent BIM-46187

Analgesic potential for PAR4 agonists

Santen patents novel strategy for allergic conjunctivitis

Recent patents impart new therapeutic agents for cancer

Recent patents divulge novel analgesic agents

Serono and Syntonix establish agreement to develop uniquely delivered FSH infertility treatment

Phase II trial under way with ASF-1096 for discoid lupus erythematosus

Cell Therapeutics establishes global alliance with Novartis for Xyotax

Clavis Pharma and Mount Sinai School of Medicine to collaborate on anticancer drugs

ArmaGen receives grant to develop first nerve gas antidote

Schering AG grants Bausch & Lomb license to SEGRA for ophthalmic use

Pfizer and Trans Tech Pharma to develop RAGE products for Alzheimer's disease

Milestone payment to AnorMED for Fosrenol approval in Germany

E.U. orphan medicinal product designation assigned to Nektar's amphotericin B inhalation powder

Opexa Therapeutics provides update on preclinical and clinical progress

ExonHit Therapeutics and Allergan strengthen strategic alliance

Organon and Schering AG to discontinue codevelopment of male hormonal contraceptive

Aastrom Biosciences reports promising interim data for Tissue Repair Cells

The VEGF antagonist bevacizumab shows promise in HHT: News in Context

Selective norepinephrine reuptake inhibitors developed by Wyeth

Connetics' Verdeso Foam approved for atopic dermatitis indication in U.S.

GlaxoSmithKline seeks FDA approval for Tykerb for advanced breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...